Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Apte

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Hepatology (Baltimore, Md.)|July 28, 2006
Upregulation of calpastatin in regenerating and developing rat liver: role in resistance against hepatotoxicityPallavi B Limaye, Vishakha S Bhave, Prajakta S Palkar, et al.
Clinical and Experimental Rheumatology|June 21, 2008
Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LVI) [corrected]R Andrade, M L Sanchez, G S Alarcón, et al.
Lupus|April 17, 2008
Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII)L B Tucker, A G Uribe, M Fernández, et al.
Gynecologic Oncology|April 30, 2013
A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapyRobert M Wenham, James Lapolla, Hui-Yi Lin, et al.
Gynecologic Oncology|March 7, 2009
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancerKathleen M Schmeler, Saroj Vadhan-Raj, Pedro T Ramirez, et al.
Rheumatology (Oxford, England)|August 2, 2006
Predictors of post-partum damage accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (XXXVIII)R M Andrade, G McGwin, G S Alarcón, et al.
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|July 28, 2022
Cumulative burden of symptomatology in patients with gynecologic malignancies undergoing chemotherapyLaura B Oswald, Sarah L Eisel, Danielle B Tometich, et al.
Gynecologic Oncology|July 24, 2013
Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrestEntidhar Al Sawah, Xin Chen, Douglas C Marchion, et al.
Plos One|November 23, 2021
Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomesDaryoush Saeed-Vafa, Douglas C Marchion, Susan M McCarthy, et al.
Journal of Gynecologic Oncology|February 23, 2012
BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatinNisha Bansal, Douglas C Marchion, Elona Bicaku, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Hepatology (Baltimore, Md.)|July 28, 2006
Upregulation of calpastatin in regenerating and developing rat liver: role in resistance against hepatotoxicityPallavi B Limaye, Vishakha S Bhave, Prajakta S Palkar, et al.
Clinical and Experimental Rheumatology|June 21, 2008
Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LVI) [corrected]R Andrade, M L Sanchez, G S Alarcón, et al.
Lupus|April 17, 2008
Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII)L B Tucker, A G Uribe, M Fernández, et al.
Gynecologic Oncology|April 30, 2013
A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapyRobert M Wenham, James Lapolla, Hui-Yi Lin, et al.
Gynecologic Oncology|March 7, 2009
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancerKathleen M Schmeler, Saroj Vadhan-Raj, Pedro T Ramirez, et al.
Rheumatology (Oxford, England)|August 2, 2006
Predictors of post-partum damage accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (XXXVIII)R M Andrade, G McGwin, G S Alarcón, et al.
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|July 28, 2022
Cumulative burden of symptomatology in patients with gynecologic malignancies undergoing chemotherapyLaura B Oswald, Sarah L Eisel, Danielle B Tometich, et al.
Gynecologic Oncology|July 24, 2013
Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrestEntidhar Al Sawah, Xin Chen, Douglas C Marchion, et al.
Plos One|November 23, 2021
Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomesDaryoush Saeed-Vafa, Douglas C Marchion, Susan M McCarthy, et al.
Journal of Gynecologic Oncology|February 23, 2012
BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatinNisha Bansal, Douglas C Marchion, Elona Bicaku, et al.
Pageof 8